Rodgers A
The George Institute for Global Health, Sydney, Australia.
ArticleKetamine
Effectiveness and safety of repeat dose subcutaneous ketamine for treatment-resistant depression, and the impact of prior ketamine treatment: open label extension of the KADS study.
ArticlePsilocybin
Patient perspectives on research gaps in cluster headache.
ArticleKetamine
Efficacy and safety of a 4-week course of repeated subcutaneous ketamine injections for treatment-resistant depression (KADS study): randomised double-blind active-controlled trial: commentary, author response.
ArticlePsychedelics
Exploring psychedelic experiences among people who regularly use methamphetamine: Findings from an international survey.
ArticleKetamine
Efficacy and safety of a 4-week course of repeated subcutaneous ketamine injections for treatment-resistant depression (KADS study): randomised double-blind active-controlled trial.
ArticleKetamine
Ensuring the affordable becomes accessible-lessons from ketamine, a new treatment for severe depression.
ArticleKetamine